营收情况 - 2024年第三季度营收90万美元主要来自CDMO服务其中80万美元为CDMO服务营收较2023年同期70万美元的CDMO营收有所增长归因于更多客户合同的工艺开发服务完成[153] - 2024年前九个月营收520万美元主要来自CDMO服务其中500万美元为CDMO服务营收较2023年同期210万美元的CDMO营收有所增长归因于圣安东尼奥生物制造业务的扩张[160] 营收成本 - 2024年第三季度营收成本90万美元2023年同期为50万美元增长源于服务范围扩大和多个CDMO合同的里程碑工作完成[154] - 2024年前九个月营收成本260万美元2023年同期为150万美元增长源于服务范围扩大和多个CDMO合同的里程碑工作完成[161] 研发费用 - 2024年第三季度研发费用430万美元2023年同期为520万美元[155] - 2024年前九个月研发费用1180万美元2023年同期为1660万美元[162] 销售、一般和管理费用 - 2024年第三季度销售、一般和管理费用560万美元较2023年同期的610万美元减少50万美元[157] - 2024年9月30日前九个月销售、一般和管理费用为1570万美元较2023年同期减少390万美元[164] 相关方或有收益应收款公允价值变动 - 2024年第三季度末相关方或有收益应收款公允价值变动增加20万美元2023年同期无变动[158] - 2024年9月30日前九个月或有收益应收款公允价值变动为120万美元2023年同期无变动[165] 非营业费用 - 2024年第三季度非营业费用90万美元2023年同期为10万美元[159] - 2024年9月30日前九个月非营业费用为80万美元2023年同期为20万美元[166] 其他项目费用 - 其他项目费用减少100万美元[163] 现金及现金等价物和短期投资 - 2024年9月30日公司有现金及现金等价物和短期投资约480万美元11月14日约为80万美元[167] 资金筹集情况 - 2024年3月、5月、8月分别筹集资金120万美元、540万美元、1310万美元[169] 净亏损情况 - 2024年9月30日前九个月净亏损2450万美元2023年同期为4120万美元[169] 现金流量情况（经营活动） - 2024年9月30日前九个月经营活动现金使用量为2070万美元较2023年同期减少980万美元[174] 现金流量情况（投资活动） - 2024年9月30日前九个月投资活动现金提供量为280万美元较2023年同期减少2730万美元[175] 现金流量情况（融资活动） - 2024年9月30日前九个月融资活动现金提供量为2230万美元2023年同期现金使用量为280万美元[176]

DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, “Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and develo ...

财报基本信息 - 财报包含截至2024年9月30日的季度财务信息[5] - 财报以新闻稿形式发布[5] - 财报信息不被视为已提交或承担相关责任[6] 财报未涉及内容 - 未提及用户数据相关内容[无] - 未提及未来展望和业绩指引相关内容[无] - 未提及新产品和新技术研发相关内容[无] - 未提及市场扩张和并购相关内容[无] - 未提及其他新策略相关内容[无] - 未提及业绩总结相关内容[无] - 未提及具体数据相关内容[无]

DURHAM, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today announced a partnership with Celltheon Corporation to provide cell line development services to clients using Celltheon’s proprietary GOLDILOCKS™ transposase-based platform. This collaboration enables clients to integrate with Scorpius’ program management team and quality system while preparing to transfe ...

DURHAM, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated biomanufacturing company, today announced the implementation of strategic cost-saving measures expected to save over $2 million annually. The recently implemented measures include the divestiture of certain non-core assets and the initiation of programs designed to optimize operational efficiency across the organization. The Company expects these measures to significantly ...

DURHAM, N.C., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today released a letter to shareholders from its CEO Jeff Wolf: "We are excited to share an update on Scorpius as we continue to position the company to take a lead role in catering to the rapidly growing biologic and cell therapy markets. Over the past several years, we have made significant investments design ...

Reduces operating expenses by 25% Pipeline surpasses $100 million in weighted opportunities across the government and manufacturing sectors DURHAM, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the second quarter ended June 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "We are extremel ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-35994 Scorpius Holdings, Inc. (Exact name of registrant as specified in its ch ...

DURHAM, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its underwritten public offering of 14,375,000 shares of common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof), including full exercise of the underwriter's overallotment option. Each share of common stock (or Pre-Funded Warrant) was offered at a publi ...

DURHAM, N.C., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the new pricing of an underwritten public offering of 12,500,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being offered at a public offering price of $1.00 per share (inclusive of the Pre-Funde ...